Otsuka (OTCMKTS:OTSKY) Shares Gap Down – What’s Next?

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $33.12, but opened at $31.4492. Otsuka shares last traded at $32.09, with a volume of 3,057 shares.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. The Goldman Sachs Group cut Otsuka from a “strong-buy” rating to a “strong sell” rating in a report on Friday, February 27th. Zacks Research upgraded Otsuka from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 31st. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Otsuka currently has a consensus rating of “Hold”.

Otsuka Trading Down 3.7%

The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.67 and a current ratio of 2.17. The stock has a market cap of $34.27 billion and a PE ratio of 13.46. The stock has a fifty day moving average price of $34.95 and a 200 day moving average price of $32.17.

Otsuka (OTCMKTS:OTSKY) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.16. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.The firm had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. Equities analysts expect that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.99 EPS for the current year.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.